Other studies have shown that the switching from basal-bolus insulin therapy to a combination of dulaglutide and basal insulin, and the switching from daily dipeptidyl peptidase-4 (DPP-4) inhibitors to weekly trelagliptin in patients with T2DM improved the DTR-QOL scores (10), (11). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.